Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
05/18/2018 05/22/2018 05/23/2018 05/24/2018 05/25/2018 Date
91(c) 92.7(c) 91.25(c) 91.35(c) 91.3(c) Last
101 938 103 614 61 060 53 402 46 730 Volume
+1.62% +1.87% -1.56% +0.11% -0.05% Change
More quotes
Financials (EUR)
Sales 2018 28,0 M
EBIT 2018 -110 M
Net income 2018 -108 M
Finance 2018 305 M
Yield 2018 -
Sales 2019 60,1 M
EBIT 2019 -84,6 M
Net income 2019 -86,7 M
Finance 2019 159 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 92,7x
EV / Sales2019 45,7x
Capitalization 2 904 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications.It operates through the Proprietary Development and Partnered Discovery segments.The Proprietary Development segment combines proprietary research and development of therapeutic... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
05/25MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
05/22MORPHOSYS : Annual General Meeting of MorphoSys AG Elects New Supervisory Board ..
AQ
05/22MORPHOSYS : Announces Presentation of Clinical Data on Proprietary Blood Cancer ..
AQ
05/18MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
05/18MORPHOSYS : to Present at Upcoming Investor Conferences
PU
05/18MORPHOSYS : to Present at Upcoming Investor Conferences
EQ
05/17MORPHOSYS AG : Annual General Meeting of MorphoSys AG Elects New Supervisory Boa..
AC
05/17MORPHOSYS : Annual General Meeting of MorphoSys AG Elects New Supervisory Board ..
PU
05/17MORPHOSYS : Annual General Meeting of MorphoSys AG Elects New Supervisory Board ..
EQ
05/17MORPHOSYS : Announces Presentation of Clinical Data on Proprietary Blood Cancer ..
PU
More news
Sector news : Biotechnology & Medical Research - NEC
05/25The Heated Quest for Opioid Alternatives -2-
DJ
05/25The Heated Quest for Opioid Alternatives
DJ
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/11Trump's Plan to Cut Drug Prices Leaves Industry Relieved
DJ
05/09Drugmaker GSK rings in more change as CFO heads for exit in 2019
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
05/25MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the Ger.. 
05/25MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the Ger.. 
05/18UPSIDE MOMENTUM ALERT: $MOR MORPHOSYS AG ADS ? TradeIdeas via  
05/18MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the Ger.. 
05/18MorphoSys to Present at Upcoming Investor Conferences  
More tweets
Qtime:36
News from SeekingAlpha
05/03MorphoSys AG's (MPSYF) CEO Simon Moroney on Q1 2018 Results - Earnings Call T.. 
05/03MorphoSys AG 2018 Q1 - Results - Earnings Call Slides 
05/03MorphoSys AG reports Q1 results 
04/19MorphoSys prices IPO at $25.04 per ADS, trading commences today 
04/14SA STOCK TO WATCH : Netflix To The Rescue? 
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 88,7 €
Spread / Average Target -2,9%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Marc Cluzel Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Wendy S. Johnson Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG21.05%3 383
CELLTRION, INC.--.--%30 812
IQVIA HOLDINGS INC4.64%21 079
LONZA GROUP1.63%20 077
INCYTE CORPORATION-29.71%14 132
NEKTAR THERAPEUTICS42.83%13 799